Contrary to assumptions, once-a-day pills for combating HIV are actually less expensive than multi-tablet regimens and also offer an added bonus — patient adherence is greater, which suggests healthier outcomes, according to a new analysis of pharmacy claims.

To wit, overall medicine costs for patient taking single-tablet regimens were $6,100 less a year when compared regimens requiring multiple pills, among those who were taking the pills as they should. On average, health plans would save $4,162 per patient each year if they switched to clinically equivalent single-tablet regimens. Meanwhile, patient adherence was nearly 75 percent among those taking once-daily pills versus 65 percent for those on multi-tablet regimens.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • After this careful explanation, the takeaway seems to be “spend more, save more.” (More money, more people … other?) This post will need a second or third reading to fully understand this conundrum.

Comments are closed.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy